Edwards Lifesciences Stock News

Edwards Lifesciences (NYSE: EW), a medical technology company specializing in artificial heart valves, currently trades at $67 per share, about 50% lower than the peak level of $131 seen in December 2021. EW has fared much worse than its peer – Medtronic stock (NYSE: MDT) – down 7% over this period.

Edwards Lifesciences faces temporary issues, but its strong market position and competitive edge make it an attractive long-term investment opportunity. The company is transitioning, focusing on its cardiovascular business after divesting its Critical Care segment and acquiring Endotronix and JenaValve. Growth opportunities include international expansion and increasing awareness of heart condi...

LONDON--(BUSINESS WIRE)--Please replace the release with the following corrected version. The updated release reads: FIRST ALL-FEMALE TAVI TRIAL SHOWS EXCELLENT OUTCOMES FOR WOMEN RECEIVING EDWARDS VALVES Edwards Lifesciences (NYSE: EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve impla...

LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve implantation (TAVI). Presenting one-year results during a Hot Line session at the ESC Congress 2024, investigators reported superior outcomes for women receiving the Edwards SAPIEN 3 Ul...

Seven months into 2024, it has still been a good year for the stock market, but the sands shifted under investors' feet during July, as a “Great Rotation” began.

While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks.

Finding value in this market is difficult because the S&P 500 has increased over 50% since its bottom in October 2022. Certainly, you won't find it in technology or mega caps, which have soared due to the AI craze.

Edwards Lifesciences cut TAVR guidance, stock price dropped by over 31%. Recent acquisitions and divestiture of the Critical Care business show strategic focus on the structural heart market. Analyst reiterates 'Strong Buy' rating with a fair value of $72 per share, confident in long-term growth potential.